Advances in Immunotherapy of Malignant Pleural Mesothelioma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2021 Aug 25

PMID 34429612

Citations 8

Authors

Dongying Liao

Yongchao Yu

Qingyun Mei

Ziwei Wang

Xiaojiang Li

Yingjie Jia

Fanming Kong

Affiliations

Soon will be listed here.

Abstract

Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patients as a first-line therapy by the FDA in October 2020. Immunotherapy is expected to be the best choice for MPM treatment. In the following article, the past treatment plan and the progress of immunotherapy for MPM will be reviewed.

Citing Articles

Case report: complete response and long-term survival on third-line immunotherapy in patient with pleural mesothelioma.

Juric culjak Z, Tomic S, Situm K, Boraska Jelavic T Front Oncol. 2024; 14:1388829.

PMID: 39267830 PMC: 11391104. DOI: 10.3389/fonc.2024.1388829.

Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy.

Torricelli F, Donati B, Reggiani F, Manicardi V, Piana S, Valli R Mol Cancer. 2023; 22(1):114.

PMID: 37460925 PMC: 10351128. DOI: 10.1186/s12943-023-01816-9.

Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma.

Rondon L, Fu R, Patel M Cancers (Basel). 2023; 15(11).

PMID: 37296902 PMC: 10251855. DOI: 10.3390/cancers15112940.

Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma.

Umeyama Y, Taniguchi H, Gyotoku H, Senju H, Tomono H, Takemoto S Front Immunol. 2023; 14:1058838.

PMID: 37006249 PMC: 10063812. DOI: 10.3389/fimmu.2023.1058838.

Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma.

Okamura K, Inoue H, Tanaka K, Ikematsu Y, Furukawa R, Ota K Cancer Sci. 2022; 114(3):1095-1107.

PMID: 36369966 PMC: 9986072. DOI: 10.1111/cas.15645.

References

Yap T, Nakagawa K, Fujimoto N, Kuribayashi K, Guren T, Calabro L . Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med. 2021; 9(6):613-621. DOI: 10.1016/S2213-2600(20)30515-4. View

Disselhorst M, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries J, van der Noort V . Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019; 7(3):260-270. DOI: 10.1016/S2213-2600(18)30420-X. View

Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G . Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer. 2010; 11(1):30-5. DOI: 10.3816/CLC.2010.n.005. View

Pezzuto F, Lunardi F, Vedovelli L, Fortarezza F, Urso L, Grosso F . P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. Front Oncol. 2021; 11:653497. PMC: 8019896. DOI: 10.3389/fonc.2021.653497. View

Santoro A, OBrien M, Stahel R, Nackaerts K, Baas P, Karthaus M . Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008; 3(7):756-63. DOI: 10.1097/JTO.0b013e31817c73d6. View

Fujimoto N, Okada M, Kijima T, Aoe K, Kato T, Nakagawa K . Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study. JTO Clin Res Rep. 2021; 2(3):100135. PMC: 8474205. DOI: 10.1016/j.jtocrr.2020.100135. View

Remon J, Reguart N, Corral J, Lianes P . Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev. 2014; 41(1):27-34. DOI: 10.1016/j.ctrv.2014.10.007. View

Arrieta O, Lopez-Macias D, Mendoza-Garcia V, Bacon-Fonseca L, Munoz-Montano W, Macedo-Perez E . A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2014; 73(5):975-82. DOI: 10.1007/s00280-014-2429-5. View

Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272):375-386. DOI: 10.1016/S0140-6736(20)32714-8. View

10.

Mansfield A, Roden A, Peikert T, Sheinin Y, Harrington S, Krco C . B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014; 9(7):1036-1040. PMC: 4058651. DOI: 10.1097/JTO.0000000000000177. View

11.

Betti M, Aspesi A, Ferrante D, Sculco M, Righi L, Mirabelli D . Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes. Genes Chromosomes Cancer. 2018; 57(11):573-583. DOI: 10.1002/gcc.22670. View

12.

Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, De Vuyst P . Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2009; 35(3):479-95. DOI: 10.1183/09031936.00063109. View

13.

van Haarst J, Baas P, Manegold C, Schouwink J, Burgers J, de Bruin H . Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002; 86(3):342-5. PMC: 2375227. DOI: 10.1038/sj.bjc.6600118. View

14.

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D . Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387(10026):1405-1414. DOI: 10.1016/S0140-6736(15)01238-6. View

15.

Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake M . Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. Lung Cancer. 2015; 88(3):344-8. DOI: 10.1016/j.lungcan.2015.03.005. View

16.

Nowak A, Lesterhuis W, Kok P, Brown C, Hughes B, Karikios D . Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020; 21(9):1213-1223. DOI: 10.1016/S1470-2045(20)30462-9. View

17.

Kim S, Bull D, Garland L, Khalpey Z, Stea B, Yi S . Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma?. Ann Thorac Surg. 2018; 107(1):194-201. DOI: 10.1016/j.athoracsur.2018.07.081. View

18.

Cedres S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A . Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One. 2015; 10(3):e0121071. PMC: 4361537. DOI: 10.1371/journal.pone.0121071. View

19.

Yang H, Xu D, Schmid R, Peng R . Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. Ther Adv Med Oncol. 2020; 12:1758835920971421. PMC: 7672749. DOI: 10.1177/1758835920971421. View

20.

Oehl K, Vrugt B, Wagner U, Kirschner M, Meerang M, Weder W . Alterations in Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma. Clin Cancer Res. 2021; 27(8):2277-2291. DOI: 10.1158/1078-0432.CCR-20-4037. View